Big Pharma takes on risk with biosimilar programs

Companies like Pfizer, Teva and Hospira are among the developers trying to get an early jump on the biosimilar drug market. A pathway for biosimilar drugs was approved when the healthcare bill was approved earlier this year, but the FDA has yet to set out clear guidelines for development of the copycat drugs. But big companies can't resist the call of the potentially lucrative market for generic biologics. Pfizer is set on creating "bio-betters," Hospira is in the process of...